Glaxo Wants to Make Smallpox, Anthrax Vaccines
WASHINTON, DC-Just days after Health and Human Services Secretary Tommy Thompson called out to pharmaceutical companies to make necessary vaccines in the wake of the Sept. 11 tragedies, British-owned GlaxoSmith Kline has announced they will accept the challenge. The pharmaceutical giant is asking federal authorities for permission to begin manufacturing both smallpox vaccines and anthrax treatments immediately.
Thompson called out to pharmaceutical companies last week, stating the US needs more than 300 million doses of the smallpox vaccine on hand in case a biological weapon was used. A GlaxoSmithKline representative said while the company does not currently have the equipment or supplies to manufacture the vaccine in question, they do have some of the best vaccine experts on staff and are responsible for making numerous other inoculations.
Glaxo officials are also testing Amoxil and Augmentin to see if these amoxicillin-based antibiotics could ease pressure off of Bayer-the manufacturer of Cipro. Cipro is currently the antibiotic of choice for more than 8,000 Americans on the eastern seaboard who are worried about possible anthrax exposure.
Officials from the Centers for Disease Control and Prevention are reporting there are actually seven other antibiotics that have shown to be effective in treating anthrax exposure.
A company representative said Glaxo would provide the antibiotics to treat anthrax exposure free of charge to the government.
Information from www.sfgate.com
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
